[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.184.210. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1986

Intravitreal Amikacin in the Treatment of Bacterial Endophthalmitis

Author Affiliations

From the Retina Service (Drs Talamo and D'Amico), the Howe Laboratory of Ophthalmology (Drs Talamo and D'Amico), and the Cornea Service (Dr Kenyon), the Massachusetts Eye and Ear Infirmary, and the Department of Ophthalmology, Harvard Medical School (Drs Talamo, D'Amico, and Kenyon), Boston.

Arch Ophthalmol. 1986;104(10):1483-1485. doi:10.1001/archopht.1986.01050220077030
Abstract

• Intravitreal administration of broadspectrum antibiotics is a widely accepted component of initial therapy for bacterial endophthalmitis. Four cases of cultureproved bacterial endophthalmitis are reported to demonstrate the safety of intravitreal administration of amikacin sulfate in conjunction with cephalosporins in patients. The benefits of using amikacin rather than gentamicin sulfate in intravitreal drug therapy are discussed, and a wider role for amikacin as the aminoglycoside of choice for initial intravitreal injection in presumed bacterial endophthalmitis is suggested.

×